CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BMS-986256Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1492 Milk of magnesia Wiki 1.00
drug341 Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy Wiki 1.00
drug1268 Itolizumab IV infusion Wiki 1.00

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Pharmacokinetics and Metabolism of a Single Dose of [14C] BMS-986256 in Healthy Male Participants

The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986856 in healthy males.

NCT04269356 Healthy Participants Drug: BMS-986256 Drug: Milk of magnesia

Primary Outcomes

Measure: Maximum observed plasma concentration (Cmax) of [14C] BMS-986256

Time: Up to 49 days

Measure: Time to attain maximum observed plasma concentration (Tmax) of [14C] BMS-986256

Time: Up to 49 days

Measure: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)) of [14C] BMS-986256

Time: Up to 49 days

Secondary Outcomes

Measure: Incidence of Adverse Events (AEs)

Time: Up to 49 days

Measure: Incidence of Serious Adverse Events (SAEs)

Time: Up to 49 days

Measure: Incidence of clinically significant changes in clinical laboratory results: Hematology tests

Time: Up to 49 days

Measure: Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests

Time: Up to 49 days

Measure: Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests

Time: Up to 49 days

Measure: Incidence of clinically significant changes in vital signs: Blood pressure

Time: Up to 49 days

Measure: Incidence of clinically significant changes in vital signs: Heart rate

Time: Up to 49 days

Measure: Incidence of clinically significant changes in vital signs: Respiratory rate

Time: Up to 49 days

Measure: Incidence of clinically significant changes in vital signs: Body temperature

Time: Up to 49 days

Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters

Time: Up to 49 days

Measure: Incidence of clinically significant changes in physical examination findings

Time: Up to 49 days

No related HPO nodes (Using clinical trials)